Investment
Features
FeesSafety
Academy
More
Pluang+

Compare McDonald's Corp (MCD) vs Novavax Inc (NVAX) Price & Performance

McDonald's CorpTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

McDonald's Corp vs Novavax Inc — how do they compare? McDonald's Corp trades at $264.12 (market cap $190.16B), while Novavax Inc trades at $8.08 (market cap $1.30B). The key difference: McDonald's Corp is far larger — about 146.3× Novavax Inc's market cap, and McDonald's Corp pays a 2.78% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.

MCDNVAX
Market Cap
$190.16B$1.30B
Volume
2,230,036
Sector
Consumer CyclicalHealth
52-Week High
$341.06$11.19
52-Week Low
$264.54$6.22
Enterprise Value
$243.87B$800.50M
Dividend Yield
2.78%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

McDonald's Corp

McDonald's (MCD) trades at $267.71, down 2.1% on the day, with a bearish technical signal driven by moving averages. The company reported steady revenue growth to $26.89 billion in 2025 and a net income margin of 31.62%, though Q2 2026 earnings are pending. Recent news highlights a new 'McDonald's NEXT' strategy focusing on automation and menu improvements to boost competitiveness.

The stock presents a buying opportunity with a consensus price target of $329, implying 23% upside, supported by strong analyst sentiment (58% buy ratings). Risks include inflationary pressures on franchisee margins and high long-term debt of $38.42 billion. Earnings execution and strategy rollout will be key for near-term performance.

Novavax Inc

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About McDonald's Corp

McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.

Read more on MCD

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX